These results suggest that during chronic administration of the racemate, the D-enantiomer 26 would accumulate, which could have negative effects. The enantiomers of many chiral drugs 27 not only exhibit different pharmacological effects in regard to targets that dictate therapeutic 28 and toxic effects, but are also handled differently in the body due to pharmacokinetic effects. 29
Introduction

51
N-acetyl-leucine has been used as an over-the-counter drug for the treatment of vertigo since 52 1957. One assumed mode of action is normalization of neuronal membrane potential and 53 excitability as was demonstrated in an animal study [1] . Recently, N-acetyl-leucine has 54 experienced a renaissance with renewed interest from both academia and industry as it is a 55 promising treatment for several disorders with unmet medical needs including cerebella 56 ataxia [2-5], cognition and mobility in the elderly [6] , lysosomal storage disorders [7, 8] and 57 migraine [9] . Given its broad therapeutic potential, aspects of N-acetyl-leucine's 58 pharmacodynamics and pharmacokinetics warrant further exploration. 59
60
As N-acetyl-leucine is an analogue of the alpha amino acid leucine, it has a stereocentre and 61 thus a pair of enantiomers (Fig 1) . Enantiomers are isomers, compounds with the same 62 molecular formula but which differ in the arrangement of their atoms in space, having one 63 chiral stereocentre with four different substituents that yields two non-superimposable mirror 64 image molecules (Fig 1) . Often the pharmacological activity of a drug resides with a single 65 enantiomer because living systems are chiral and formed from chiral constituents [10] . Thus, 66 proteins made from L-amino acids are chiral and show stereoselective binding of drugs to 67 transporters, receptors and enzymes. Stereoselective binding can be trivial or profound: S-68 asparagine is sweet whereas R-asparagine is bitter; R-thalidomide is a sedative whereas the 69 S-form is teratogenic [11] . The thalidomide tragedy shifted the importance of drug chirality 70 from inconsequential to crucial [12] as reflected by the current requirements for developing 71 single enantiomers in drug development and regulatory approval [13, 14] Amide resonance structures showing similarity to an imine. Extending from the tetrahedral 75 chiral carbon is a solid wedge to indicate a bond projecting above the plane of the paper and a 76 hashed wedge to indicate a bond projecting below the plane of the paper. 77
78
The effects of chirality on drug behaviour has shifted from nice to know to effectively need 79 to know for informed dosing and regulatory compliance, safety and efficacy. As N-acetyl-80 leucine was developed before realization of the importance of drug chirality, it was and 81 continues to be marketed as a racemate (Tanganil ® , Laboratoires Pierre Fabre) [15] . 82
Subsequent studies in models of vertigo on the individual enantiomers have revealed that the 83 therapeutic effects of N-acetyl-DL-leucine are due to the L-enantiomer [16, 17] . This means 84 that, as expressed by Ariens [12] for chiral drugs in general, the racemic mixture (N-acetyl-85 DL-leucine) is in fact two drugs (the L-enantiomer and the D-enantiomer), each with distinct 86 properties with one (N-acetyl-D-leucine) at best does not contribute to the therapeutic 87 response, and at worst potentially responsible for toxicity, as this inactive enantiomer 88 provides 'therapeutic ballast' [18] . 89 90 Chirality affects not only the pharmacodynamic properties of potency, efficacy and affinity, it 91 also affects pharmacokinetic processes of absorption, distribution, metabolism and excretion 92 Samples were injected as a 4-µL volume and eluted with a gradient of buffer A (20 mM 151 ammonium acetate) and buffer B (methanol) with a flow rate of 0.3 mL/min and column 152 oven temperature of 30°C. The gradient was 80% A at 0 min; 20% A at 3.5 min and 80% A 153 Exactive hybrid Orbitrap MS and a Waters Acquity HSS T3 column (50 x 2.1 mm, 1.8 µm 164 particle size). MS was as described above over the mass range of 70-1000 using an Table 1 ) and AUC of 75800 h*ng/mL versus 2560 h*ng/mL ( Fig 5d and Table 1 ). The 207 elimination rate was similar for both enantiomers, indicated by the linear and parallel curves 208 Table 1 ). The D-enantiomer remained detectable until 8 h 211 (Fig 5g) with the last concentration of 247 ng/mL (Fig 5f) . In contrast, the L-enantiomer 212 remained detectable until 2 h (Fig 5g) with the last concentration of 623 ng/mL (Fig 5f) . Table 1 ) and an AUC 251 of 573 h*ng/mL and 11400 h*ng/mL ( Fig 5d and Table 1 ). As with administration with the 252 racemate (Fig 3a and 3b ), after dosing with purified L-enantiomer, the elimination rate was 253 similar for both enantiomers, indicated by the linear and parallel curves on a semilog graph 254 Table 1 ). Both enantiomers remained detectable in the 257 plasma until 8 h and 6 h ( Fig 5g) with a last concentration of 16 ng/mL and 168 ng/mL ( Fig  258   5f ). However, the Clast and Tlast are somewhat misleading for all measurements, as in looking 259 at the profiles, the main elimination was over for all enantiomers at around 2 h when these 260 terminal concentrations were reached (Fig 3b and 3d) . Table 1 ) and 101 fold for AUC (57800/573; Table 1 ). The L-enantiomer was dosed as 50% of 274 the administered racemate and 97.4% of the administered purified L-enantiomer, for a 275 difference in dose proportionality of 1.9-fold. The actual dose proportionality was 4.9-fold 276 for Cmax (16800/3410; Table 1 and Fig 5j) To facilitate comparison of the racemate with the purified L-enantiomer, we re-plotted the 282 plasma concentration versus time profiles of the two enantiomers on the same graph over the 283 first two hours (Fig 4) . The amount of D-enantiomer was the plasma is significantly higher 284 when dosed with the racemate compared to the much lower amount present when dosed with 285 purified L-enantiomer, and is consistent with the measured 2.6% D contamination in the 286 purified L-enantiomer (S1 Fig) . The semilog plot nicely shows the equal rates of elimination 287 at all concentrations and times, demonstrating that the D-enantiomer is not affected by dosing 288 with either the DL or L form. As would be expected with administering a 97.4% to 2.6% 289 mixture of N-acetyl-L-leucine to N-acetyl-D-leucine, the L-enantiomer dominated in the 290 plasma (Fig 4a and 4b ). Administration of DL or L alone only affected Cmax and AUC, but 291 did not affect elimination (ke o T1/2). Plotting the L-enantiomer in the plasma on the same 292 graph to compare dosing with DL with L alone (Fig 4c) , graphically shows the dramatic 293 differences in Cmax and AUC, but show the same rate of elimination (parallel curves when fit 294 to a noncompartmental model). racemate, the ratio of D/L enantiomer was about 25 for both Cmax (Fig 5h; 26 versus 1 , p = 307 0.014) and AUC (Fig 5i, 25 vs 1 , p = 0.015). As the purified L-enantiomer administered 308 contained 97.4% L-enantiomer and 2.6% D-enantiomer (S1 Fig), if the enantiomers had 309 identical pharmacokinetics, the ratio of L/D would be predicted to be 36 (that is, 97.4/2.6). 310
When administered as the purified L-enantiomer, the ratio of L/D was 32 for Cmax (Fig 5h;  311 31.7 versus 36, p = 0.17) and 20 for AUC (Fig 5i; 19 .8 versus 36, p = 0.006). 312 313
Enantiomers show differences in distribution and metabolism 314
To investigate the effect of administering either the racemate or purified L-enantiomer of N-315 acetyl-leucine on the distribution of the enantiomers, muscle and brain were analysed. At 316 specific times after oral dosing, the mice were euthanized and the amount of D-and L-317 enantiomer present in the tissues was determined. Following oral dosing with the racemate, 318 muscle contained much more D-enantiomer than L-enantiomer (Fig 6a) . In muscle, the D-319 enantiomer was only detectable at 30 min and 2 h (Fig 6a) . In contrast, following oral dosing 320 of the L-enantiomer alone, in muscle, the L-enantiomer was not detected at any time point 321 and the D-enantiomer was detectable but at a much lower concentration (Fig 6c) than after 322 administration of the racemate (Fig 6a) . Neither the D-nor L-enantiomer was detected in 323 muscle after 2 hours from the time or dosing (Fig 6a and 6c) . Following oral dosing with the 324 racemate, the brain contained detectable D-enantiomer at only the 30 min time point and L-325 enantiomer was not detectable at any time point (Fig 6b) . Following oral dosing with purified 326 L-enantiomer, neither of the enantiomers were detected at any time point (Fig 6d) . We investigated the pharmacokinetics of the enantiomers of N-acetyl-leucine after oral 339 administration of the racemate, which has been marketed under the name Tanganil ® for the 340 treatment of vertigo in France since 1957 [15] , and the purified L-enantiomer, which is the 341 pharmacologically active enantiomer in models of acute vertigo [16, 17] . We report 342 significant and unexpected differences in the pharmacokinetics of the enantiomers. The major 343
findings of this study are as follows: First, when administered as the racemate (N-acetyl-DL-344 leucine), the D-enantiomer was present at much higher plasma maximal concentration (Cmax) 345
and (area under the curve; AUC) relative to the L-enantiomer, resulting in greater total 346 exposure. Second, when administered as purified N-acetyl-L-leucine, both the Cmax and the 347 AUC for N-acetyl-L-leucine were higher compared to administration as the racemate, even 348 when scaled for the relative dose. Third, both enantiomers distributed to the tissues 349 monitored, muscle and brain, but the D-enantiomer was found at much higher concentrations 350 relative to the L-enantiomer in both tissues. 351
352
Origin of the differences in Cmax and AUC
353
The larger AUC for N-acetyl-L-leucine when administered as the purified enantiomer 354 compared to when administered as the racemate, and factoring in the actual amounts of L-355 enantiomer present in each (that is, 97.6% and 50%, respectively), is fully accounted for the 356 by increase in Cmax because after Cmax and Tmax, the clearance (ke and T1/2) is the same for 357 both enantiomers. In other words, after 15 min, the pharmacokinetic parameters are the same 358 for both enantiomers. Therefore, the large differences in Cmax have to be due to processes 359 occurring in the first 15 min and before the L-enantiomer enters the plasma. Consequently, 360
we can deduce that the D-enantiomer is interfering with the bioavailability (the amount of 361 drug orally administered that is systemically available) of the L-enantiomer during the first 362 15 min following oral administration. Differences between enantiomers indicate interaction 363 with protein targets; therefore, two possible explanations that are not mutually exclusive 364 exist: competition at a carrier on cells in the intestine and/or differences in first-pass 365 metabolism. 366 367 Stereoisomer-mediated pharmacokinetics arising from uptake 368 The bioavailability of a drug is determined by its ability to penetrate and cross the 369 gastrointestinal epithelial cell membrane, either by passive diffusion or via a carrier. Uptake 370 by passive diffusion is determined by physicochemical properties, primarily hydrophobicity, 371 which allows penetration of the membrane's core [21, 22] . The N-acetylation of leucine 372 would be predicted to greatly increases passive membrane transport, as it eliminates one 373 (NH3 + ) of the two (NH3 + and COO -) charges present on all amino acids at physiological pH, 374 which can increase transport rates up to 10 10 -fold [23,24]. However, as this physicochemical 375 effect (loss of charge and increase in hydrophobicity) is identical for the enantiomers, it 376 cannot underlie the differences observed in the pharmacokinetics of the N-acetyl-leucine 377 enantiomers. In contrast, uptake by carriers requires molecular recognition at saturable 378 binding sites and would give rise to interference between the enantiomers. The identity of the 379 carrier for N-acetyl-leucine on the intestinal brush-border membrane is unknown; however, 380
given that N-acetyl-leucine is a modified amino acid, the most likely candidates are amino 381 acid transporters, as 52 families exist that show distinct substrate selectivity [25] [26] [27] . These 382 possibilities can be narrowed down further based on the effect of N-acetylation, which forms 383 an amide bond (Fig 1) . An amide bond would both make N-acetyl-leucine appear more like a 384 dipeptide and, through resonance, given the C-N bond partial double bond character with a 385 bond order 1.5 [28], making it an analogue of an imine (Fig 1b) . These predict that N-acetyl-386 leucine would be a substrate for the low affinity/high capacity a H + -coupled di/tripeptide 387 transporter termed PepT1, which is highly expressed and responsible for 80% of all amino 388 acids are taken up from the small intestine lumen, or an imino acid transporter which has 389 100-fold greater affinity for N-modified amino acids and shows only 2-fold stereoselectivity 390 Another likely contributing process accounting for the differences between enantiomers in 395 Cmax and AUC is first-pass metabolism [18] . As first-pass metabolism is an enzymatic 396 process, it exhibits molecular recognition at saturable binding sites and would also give rise 397 to interference between the enantiomers. Such stereoselective first-pass effects are known to 398 alter oral drug bioavailability of the enantiomers of propranolol and verapamil [19, 30] . 399
Indeed, the 2-3-fold stereoisomer effect we detected for N-acetyl-leucine is similar to the 2-3 400 fold greater oral bioavailability of (-)-verapamil compared to (+)-verapamil caused by first-401 pass metabolism [19] . Most often first-pass metabolism is mediated by cytochrome P-450 402 oxidation in the stomach, intestine or liver [18]; however, N-acetyl-L-leucine is more likely 403 handled like a nutrient than a xenobiotic, as it is a naturally occurring metabolite of L-leucine 404 and a transacetylase has been reported that interconvert N-acetyl-L-leucine and L-leucine, 405 using other L-amino acids as the substrate or product [31, 32] . Therefore, a likely enzyme for 406 first-pass metabolism of N-acetyl-L-leucine would be the acylase reported in intestinal strips 407 that was able to remove the acetyl group from most amino acids [33] , and showed 40,000-408 fold selectivity for L-amino acids over D-amino acids [31, 32, 34] . 409 410 Stereoisomer effects manifested by tissue uptake and metabolism 411 In regard to the presence of the enantiomers in muscle and brain, the amounts were much 412 lower than in the plasma (10-fold to undetectable), and the D-enantiomer was present at a 413 much higher concentration than the L-enantiomer. In general, our results showing that N-414 acetyl-leucine is blood-brain barrier permeable are consistent with studies in monkeys in 415 which radioactive racemic N-acetyl-leucine was administered intravenously and radioactivity 416 was subsequently detected in the brains [35] . However, the 14 C label was in the alpha carbon 417 of leucine and autoradiography was used for quantification, so there is no ability to determine 418 whether the radioactivity was due to N-acetyl-DL-leucine itself or a metabolite [35] . 419 Therefore, the data with radioactivity is ambiguous in terms of both the effect of 420 stereoisomerism and whether N-acetylation promotes uptake and whether it is rapidly 421 metabolized to L-leucine. 422
423
In contrast to the situation with uptake from the gut to the plasma in which the D-enantiomer 424 was reducing uptake, in muscle and brain, the presence of the D-enantiomer was associated 425 with increased presence of N-acetyl-L-leucine. Uptake from the plasma into cells and tissues, 426
as described for the intestinal cells above, occurs through both passive diffusion and carriers. 427
The explanation of competitive inhibition for a common carrier used for the asymmetry in 428 uptake between the enantiomers into the plasma of competition cannot explain this 429 observation. Indeed, such an effect would result in less of the L-enantiomer, not more, when 430 N-acetyl-D-leucine was also present. A more likely explanation is competitive inhibition of 431 the enantiomers at an enzyme that metabolizes N-acetyl-L-leucine. A likely explanation is 432 that the D-enantiomer is inhibiting the deacetylation of N-acetyl-L-leucine. It is also 433 important to note that the amount of N-acetyl-L-leucine in tissues is a steady state measure of 434 the compound, and relates not to lack of uptake but rather rapid utilization. By comparison, 435 the D-enantiomer was present in higher amounts, consistent with it being metabolically inert 436 based on feeding N-acetyl-D-leucine to rats, where it was excreted in the urine unchanged 437
[32]. The simplest explanation is that the N-acetyl-L-leucine is rapidly converted to L-leucine 438 and utilized in metabolism. Rapid utilization and metabolism of L-leucine is consistent with 439 the results of a study using stable isotope-labelled leucine itself upon oral administration [36] . 440
Moreover, our inability to detect metabolites is consistent with the disappearance of N-acetyl-441 L-leucine though metabolism to L-leucine, which would be undetectable on the background 442 of endogenous L-leucine. Slowing the conversion of N-acetyl-L-leucine to L-leucine, and 443 subsequently its regulatory effect on muscle protein synthesis and oxidative metabolism 444
[37,38], and possibly impact on its efficacy as a drug. Taken together, these data showing low 445 amounts of N-acetyl-leucine in the brain and muscle suggest that the mechanism of action of 
